Psychedelic therapies are nearing market adoption, but healthcare infrastructure still lacks the staffing, workflows, reimbursement models, and digital systems needed to deliver them at scale

Psychedelic therapies are approaching clinical and commercial reality, but the healthcare system still lacks the infrastructure to deliver them safely and efficiently at scale. Staffing models, therapist training, clinic operations, scheduling, billing, reimbursement, and digital care pathways remain underdeveloped compared with the intensity and duration these treatments require. MDMA- and psilocybin-based care create unusual operational demands because treatment often includes extensive preparation, long monitored sessions, and structured integration afterward. Providers, health systems, and technology vendors therefore need new workflows, documentation tools, room utilization models, and payment structures that fit high-touch behavioral care rather than conventional outpatient medicine. Scalable adoption depends not only on regulatory progress or clinical evidence, but also on practical systems that support access, compliance, and sustainable delivery. Without that backbone, promising therapies may remain bottlenecked even if patient demand and medical interest continue to grow.